Blood Cancer Journal, Год журнала: 2024, Номер 14(1)
Опубликована: Сен. 12, 2024
Язык: Английский
Nature Reviews Drug Discovery, Год журнала: 2024, Номер 23(4), С. 301 - 319
Опубликована: Март 6, 2024
Язык: Английский
Процитировано
131
mAbs, Год журнала: 2024, Номер 16(1)
Опубликована: Янв. 5, 2024
The 'Antibodies to Watch' article series provides an annual summary of commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical development, regulatory review, and those recently granted a first approval any country. In this installment, we discuss key details for 16 2023, as November 17 (lecanemab (Leqembi), rozanolixizumab (RYSTIGGO), pozelimab (VEOPOZ), mirikizumab (Omvoh), talquetamab (Talvey), elranatamab (Elrexfio), epcoritamab (EPKINLY), glofitamab (COLUMVI), retifanlimab (Zynyz), concizumab (Alhemo), lebrikizumab (EBGLYSS), tafolecimab (SINTBILO), narlumosbart (Jinlitai), zuberitamab (Enrexib), adebrelimab (Arelili), divozilimab (Ivlizi)). We briefly review 26 product candidates which marketing applications are under consideration at least one country or region, 23 investigational that forecast enter by the end 2024 based on company disclosures. These nearly 50 include numerous innovative bispecific antibodies, such odronextamab, ivonescimab, linvoseltamab, zenocutuzumab, erfonrilimab, antibody–drug conjugates, trastuzumab botidotin, patritumab deruxtecan, datopotamab MRG002, well mixture two immunocytokines (bifikafusp alfa onfekafusp alfa). also phase transition overall success rates therapeutics, crucial biopharmaceutical industry because these inform decisions about resource allocation. Our analyses indicate molecules have range 14–32%, with higher associated antibodies developed non-cancer indications. Overall, our data suggest therapeutic development efforts robust increasingly successful.
Язык: Английский
Процитировано
87
American Journal of Hematology, Год журнала: 2024, Номер 99(9), С. 1802 - 1824
Опубликована: Июнь 28, 2024
Multiple myeloma accounts for approximately 10% of hematologic malignancies.
Язык: Английский
Процитировано
68
Blood Cancer Discovery, Год журнала: 2023, Номер 4(6), С. 440 - 451
Опубликована: Сен. 28, 2023
Abstract BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple myeloma; however, serious infections have emerged as important toxicities. In this retrospective study, we characterized all and their risk factors, evaluated the impact of infection prophylaxis patients treated with BiAbs. Among 37 patients, 15 (41%) experienced a grade 3–5 infection, two infection-related deaths during deep remissions. Most (84%) occurred disease The cumulative probability increased over time no plateau. responders (n = 26), profound hypogammaglobulinemia 100% continued throughout entire duration treatment. During periods when were receiving intravenous immunoglobulin (IVIg), rate was 90% lower than observation (incidence ratio, 0.10; 95% confidence interval, 0.01–0.80; P 0.0307). No other factors for identified. This study demonstrates that is universal BiAbs, potentially abrogating most risk. Significance: To best our knowledge, first to comprehensively analyze mitigation strategies prevent myeloma anti-BCMA antibodies. Profound prolonged among responders, while replacement associated rates infections. See related commentary by Garfall Stadtmauer, p. 427 . article featured Selected Articles from Issue, 419
Язык: Английский
Процитировано
51
Blood Cancer Journal, Год журнала: 2024, Номер 14(1)
Опубликована: Март 5, 2024
Abstract The objective of our study was to report real-world data on the safety and efficacy standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM). This is a multi-institutional retrospective cohort included all consecutive that received at least one dose up until August 2023. One hundred ten were included, whom, 86% had triple-class refractory disease, 76% penta-refractory 35% prior exposure B-cell maturation antigen (BCMA)-targeting therapies. overall response rate (ORR) 62%, ≥ very good partial remission (VGPR) 51%. ORR without BCMA-targeted therapies 54% vs 67%, respectively ( p = 0.23). At median follow-up 3.5 months (range, 0.39–10.92), estimated 3 month 6 progression free survival (PFS) 57% (95% CI, 48%, 68%) 52% 42%, 64%) respectively. incidence cytokine release syndrome (CRS) immune effector cell associated neurotoxicity (ICANS) 56% 11% respectively, grade ≥3 CRS ICANS noted 3.5% 4.6% 78 unique infections diagnosed 44 patients, all-grade being 40% 26% Primary prophylaxis intravenous immunoglobulin (IVIG) significantly lower infection risk multivariate analysis (Hazard ratio [HR] 0.33; 95% CI 0.17, 0.64 ; 0.001).
Язык: Английский
Процитировано
47
Transplantation and Cellular Therapy, Год журнала: 2023, Номер 30(3), С. 308.e1 - 308.e13
Опубликована: Дек. 26, 2023
Язык: Английский
Процитировано
42
Nature Medicine, Год журнала: 2024, Номер 30(6), С. 1593 - 1601
Опубликована: Апрель 26, 2024
Язык: Английский
Процитировано
42
Leukemia, Год журнала: 2024, Номер 38(2), С. 365 - 371
Опубликована: Янв. 20, 2024
Язык: Английский
Процитировано
39
Nature Reviews Clinical Oncology, Год журнала: 2024, Номер 21(7), С. 539 - 560
Опубликована: Май 31, 2024
Язык: Английский
Процитировано
35
Journal of Clinical Oncology, Год журнала: 2024, Номер 42(14), С. 1665 - 1675
Опубликована: Фев. 15, 2024
Although chimeric antigen receptor T therapy (CAR-T) cells are an established for relapsed/refractory multiple myeloma (RRMM), there no models predicting outcome to identify patients who may benefit the most from CAR-T.
Язык: Английский
Процитировано
33